AKBA stock forecast, quote, news & analysis
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company... Show more
Why Akebia Therapeutics (AKBA) Stock Is Down -14% in the Last 30 Days
Key Takeaways
- Akebia Therapeutics (AKBA) shares fell roughly 14% over the last 30 days, from a close near $0.89 on September 29 to about $0.76 by late October, even after a sharp late-month rebound.
- The decline reflects sustained pressure on legacy product Auryxia from generic competition and lingering investor uncertainty about the pace of Vafseo adoption.
- A late-October rebound was fueled by favorable VOICE trial safety data presented at the American Society of Nephrology (ASN) Kidney Week.
- Over the trailing quarter, the stock has dropped roughly 40% from levels near $1.26 in late July, weighed down by mixed second-quarter results and a narrower clinical pipeline.
- Second-quarter 2026 results showed revenue of $49.1 million (down 21.4% year over year) and a net loss of $8.9 million, as Vafseo growth was offset by declining Auryxia sales.
- Wall Street still holds a broadly bullish view, with a consensus Strong Buy rating and an average price target near $3.90, well above recent trading levels.
- For additional detail on valuation, results, and projections, explore Akebia's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how algorithmic strategies approach AKBA and thousands of other tickers.
Akebia Therapeutics (AKBA) Company Overview and Market Position
Akebia Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for kidney disease. Its two marketed products anchor the business: Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for anemia associated with chronic kidney disease in dialysis patients, and Auryxia (ferric citrate), an older product for phosphorus control and iron deficiency anemia. Vafseo is the company's primary growth driver, while Auryxia faces generic competition and pricing pressure. The company also maintains a rare kidney disease pipeline that includes ebribafusp (AKB-097), a tissue-targeted complement inhibitor, and praliciguat, an sGC stimulator in development for focal segmental glomerulosclerosis. Investors follow AKBA closely for Vafseo's launch trajectory, reimbursement dynamics under the TDAPA program, and upcoming clinical readouts.
Akebia Therapeutics (AKBA) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, AKBA declined from a closing price of $0.8861 on September 29 to roughly $0.76 by late October, a drop of about 14%. The move was not linear: shares slid through most of October, reaching a closing low near $0.56 on October 22, before rebounding sharply in the final week of the period on positive clinical news.
The quarterly picture is more severe. From a level near $1.26 in late July, the stock has fallen approximately 40% through late October. Most of that decline occurred in early August, when second-quarter results and a pipeline update triggered a sharp selloff. Subsequent months brought continued erosion, followed by a partial recovery in late October that left shares well below their summer levels.
What Drove AKBA Stock Price in the Last 30 Days
The 30-day move reflects two competing forces. Early in the window, shares remained under pressure as investors digested the implications of generic competition on Auryxia and questioned whether Vafseo growth could offset that decline quickly enough. The stock slid steadily through mid-October, touching a multi-week low.
Sentiment shifted in late October. U.S. Renal Care presented an analysis of the VOICE trial demonstrating favorable safety outcomes for patients treated with vadadustat versus an erythropoiesis-stimulating agent during a late-breaking session at ASN Kidney Week. The presentation reinforced the clinical case for Vafseo and helped spark a rebound that lifted shares from their October lows. Around the same time, Piper Sandler reiterated a Buy rating with a $4.00 price target. The combined effect of positive data and supportive analyst commentary drove the late-period recovery, though the stock remained down roughly 14% over the full 30 days.
What Drove AKBA Stock Performance Over the Last Quarter
The quarterly decline was driven primarily by the company's second-quarter 2026 results, reported in early August. Total revenue fell to $49.1 million from $62.5 million a year earlier, and the company swung to a net loss of $8.9 million. Vafseo grew strongly—net product revenue rose roughly 60% year over year to $21.3 million—but Auryxia sales declined about 46% to $25.5 million amid generic competition. The report also coincided with the discontinuation of the VALOR trial, which had evaluated a therapy in non-dialysis CKD patients, narrowing a potential expansion opportunity. The shares dropped sharply in after-hours trading following the results, and Leerink subsequently downgraded the stock to Market Perform with a $1.00 price target. Despite these setbacks, broader analyst sentiment remained positive, and encouraging interim VOICE trial results kept the longer-term Vafseo thesis intact.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of the platform's most relevant automated trading strategies. Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers, but only top-performing and most pertinent bots appear in this featured section. These bots vary in strategy, holding timeframe, and performance metrics, giving traders the ability to explore different systematic approaches rather than a single one-size-fits-all signal. For investors tracking a volatile name like AKBA, automated tools can offer an additional, data-driven perspective on price action and momentum. Visit Trending AI Robots to review the currently featured strategies and their performance.
AKBA Stock Forecast Drivers: What Investors Should Watch Next
Several factors are likely to shape Akebia's outlook. Vafseo's commercial trajectory remains central, including patient and prescriber growth and the transition from TDAPA reimbursement toward the dialysis bundle in 2027. On the clinical front, top-line results from the VOCAL study are expected by the end of 2026, followed by VOICE trial results in early 2027. Investors are also monitoring the Phase 2 basket trial of ebribafusp and the Phase 2 praliciguat study, with initial data expected in 2027. On the financial side, the pace of Auryxia erosion, cash runway—reported at roughly $155.5 million at the end of the second quarter—and any refinancing or capital-raising activity will be important. Analyst price targets and rating changes may continue to influence sentiment given the wide gap between consensus targets and the current share price.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AKBA's Stochastic Oscillator is remaining in overbought zone for 1 day
Expect a price pull-back in the near future.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKBA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for AKBA entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AKBA's RSI Oscillator exited the oversold zone, 31 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on AKBA as a result. In 60 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for AKBA just turned positive on October 28, 2026. Looking at past instances where AKBA's MACD turned positive, the stock continued to rise in 35 of 42 cases over the following month. The odds of a continued upward trend are 83%.
Following a +18.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where AKBA advanced for three days, in 224 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
AKBA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.825) is normal, around the industry mean (8.329). P/E Ratio (-5.887) is within average values for comparable stocks, (-1.568). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (1.115) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. AKBA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKBA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of drugs for the treatment of anemia and vascular diseases
Industry PharmaceuticalsGeneric